Shares of Novocure Ltd. (NASDAQ:NVCR) got a boost last week – jumping 37 percent Monday – on a slew of data presented at the American Association for Cancer Research meeting in Washington, including final pivotal results in newly diagnosed glioblastoma (GBM) that included five-year survival data for its Optune device. That could help improve the status of the technology with payers and physicians, whose embrace hasn’t been uniform thus far.